10-Q: Rest EZ Reports Zero Revenue, Going Concern Doubts

Rest EZ, Inc. reported no revenue for the quarter ended September 30, 2025, alongside significant internal control weaknesses and substantial doubt about its ability to continue as a going concern.

Summary

• Reported zero revenue and zero gross profit for the three and six months ended September 30, 2025, consistent with the prior year's comparable periods.
• Net loss was $0 for the three and six months ended September 30, 2025, compared to a net loss of $33 for the same periods in 2024.
• Cash balance remained at $300 as of September 30, 2025, with total assets and stockholders' equity also at $300.
• Accumulated deficit stood at $286,101 as of September 30, 2025.
• Management identified substantial doubt about the company's ability to continue as a going concern without additional capital.
• Disclosure controls and procedures were deemed ineffective as of September 30, 2025, with material weaknesses including insufficient accounting resources, lack of segregation of duties, absence of an independent board or audit committee, and undocumented internal control policies.
• The company operates with a single product, Rest EZ Sleep Aid Supplement, manufactured by an unaffiliated outside provider, and has no proprietary intellectual property.
• Dylan Carson was appointed President, replacing Brandon Sosa, effective July 2, 2025, and also serves as CEO and CFO.

Sentiment

Score: 1

Explanation: The company exhibits severe financial distress with zero revenue, minimal cash, and an accumulated deficit. The explicit 'going concern' warning, coupled with ineffective internal controls and a lack of proprietary assets, indicates an extremely high risk of business failure.

Positives

• The company has commenced full production and distribution of its single product, Rest EZ Sleep Aid Supplement, to wholesalers, retailers, and online.
• The corporate office is provided free of charge by the Company's CEO, reducing overhead costs.
• Management has a stated plan to build its reputation and expand sales to additional wholesalers, retail chain stores, and directly to the public over the next twelve months.

Negatives

• Zero revenue and gross profit reported for the three and six months ended September 30, 2025.
• Minimal cash balance of $300 and total assets of $300 as of September 30, 2025.
• Accumulated deficit of $286,101 as of September 30, 2025.
• Substantial doubt about the company's ability to continue as a going concern without additional capital.
• Disclosure controls and procedures were ineffective as of September 30, 2025.
• Material weaknesses in internal control over financial reporting, including lack of sufficient accounting resources, lack of segregation of duties, absence of an independent board or audit committee, and undocumented internal control policies.
• The company has no proprietary intellectual property for its product, making it vulnerable to competition.
• Heavy dependence on the sole executive officer and director, Dylan Carson, for all key management functions.
• Significant competition from large, established companies with substantial capabilities and long earnings records in the sleep aid supplement market.

Risks

• Inability to raise capital necessary to sustain anticipated operations and implement the business plan.
• Inability to implement the business plan effectively.
• Inability to generate sufficient cash to pay lenders and other creditors.
• Difficulty in employing and retaining qualified management and employees.
• Dependence on the efforts and abilities of current employees and executive officers, particularly the sole executive officer and director.
• Changes in government regulations applicable to the business.
• Changes in the demand for services and different food trends.
• The degree and nature of competition in the sleep aid supplement market.
• Lack of diversification of the business plan (single product).
• General volatility of the capital markets and challenges in establishing a market for shares.
• Disruption in economic and financial conditions from past terrorist attacks, threats of future attacks, police and military activities overseas, other disruptive worldwide political and economic events, health pandemics, and environmental weather conditions.
• The product is not FDA approved, which, while not currently required, could be a competitive disadvantage or regulatory risk if requirements change.

Future Outlook

The company plans to build its reputation and expand sales to additional wholesalers, retail chain stores, and directly to the public over the next twelve months. However, these plans are contingent on the company's ability to raise additional capital, without which it may not be able to remain in business.

Management Comments

• "The Company has begun to recognize revenue, but without additional capital, the Company may not be able to remain in business."
• "Achievement of Rest EZ, Inc.'s business objective is basically dependent upon the judgment, skill and knowledge of the Company's management."
• "Mr. Carson is currently the Company's sole executive officer and director. There can be no assurance that a suitable replacement could be found for our sole executive officer and director upon his retirement, resignation, inability to act on our behalf, or death."
• "We believe our product is superior to that of the competition due to the product being in a soft gel form, avoiding substantial product break down before digestion as happens with many competitors products."

Industry Context

Rest EZ, Inc. operates in the competitive sleep aid supplement market, which includes large, established companies with significant resources and long track records. The company's lack of proprietary intellectual property and reliance on a single product manufactured by a third party places it at a disadvantage against these larger players. The industry is subject to general FDA requirements for dietary supplements, but Rest EZ's product does not require specific FDA approval, which avoids a lengthy and costly process but also means it hasn't undergone that level of scrutiny.

Comparison to Industry Standards

• **Revenue Generation:** Rest EZ, Inc.'s zero revenue for the quarter and six months ended September 30, 2025, falls significantly below industry standards for operational companies, especially those claiming 'full production and distribution.' Comparable companies in the dietary supplement space typically report consistent revenue streams.
• **Profitability:** The company's consistent net loss and accumulated deficit of $286,101 indicate a lack of profitability, which is far from industry benchmarks for sustainable businesses.
• **Capitalization:** A cash balance of $300 and total assets of $300 are extremely low for a publicly traded company, suggesting severe undercapitalization compared to industry peers.
• **Corporate Governance & Internal Controls:** The identified material weaknesses in internal controls, including lack of segregation of duties and an independent board/audit committee, are critical deficiencies that fall well below acceptable corporate governance standards for public companies, regardless of size.
• **Product Differentiation:** While management believes its soft gel form offers superiority, the absence of proprietary intellectual property makes it vulnerable to competition and limits its long-term competitive advantage compared to companies with patented formulations or unique delivery systems.

Management Changes

Corporate Governance

Related Party Transactions

• Former President Brandon Sosa's loan of $0 to the company was forgiven and deemed satisfied through shares of stock he retained.
• The corporate office at 8928 Black Pine Street, West Jordan, Utah 84088, is being provided free of charge by the Company's CEO.

Stakeholder Impact

• **Shareholders:** Significant negative impact due to zero revenue, going concern doubts, ineffective internal controls, and lack of proprietary assets, indicating high risk and potential for complete loss of investment.
• **Employees:** High uncertainty regarding job security given the company's financial instability and dependence on a single executive officer.
• **Customers:** Potential risk of product availability issues or cessation of operations if the company fails to secure additional capital.
• **Suppliers:** Risk of non-payment or cessation of orders if the company's financial situation does not improve.
• **Creditors:** High risk of default given the company's minimal cash and going concern issues, although current liabilities are reported as $0.

Next Steps

• Build out reputation further.
• Expand to additional wholesalers.
• Expand to additional retail chain stores.
• Expand sales to the public.
• Identify future investment opportunities.
• Obtain necessary debt and/or equity financing.
• Generate profits from future operations.

Key Dates

Recommendation

The company exhibits severe financial distress with zero revenue, minimal cash, and an accumulated deficit. The explicit 'going concern' warning, coupled with ineffective internal controls and a lack of proprietary assets, indicates an extremely high risk of business failure. There are no discernible positive catalysts, and the competitive landscape is formidable. An investment in Rest EZ, Inc. at this juncture carries an exceptionally high probability of capital loss.

Keywords

Rest EZ, Inc., 10-Q, sleep aid supplement, going concern, internal controls, zero revenue, net loss, corporate governance, dietary supplement, Dylan Carson, SEC filing